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Abstract: The objective of this study was to evaluate the performance of the RESIST-5 O.K.N.V.I. assay
for identifying these five common domestic carbapenemases among a large number of clinical isolates
in South Korea. A total of 268 non-duplicated clinical isolates of gram-negative bacilli were included
in this study as follows: 258 carbapenemase-producing (CP) strains (OXA-48-like, KPC, NDM, VIM,
IMP, GES, OXA-23 and two or more carbapenemase producers) and 10 non-CP carbapenem-resistant
Enterobacterales (non-CP CREs). Overall sensitivity and specificity were 98.4% and 100%, respectively.
In addition, all non-targeted carbapenemase producers including GES and OXA-23 producers and
non-CP CREs were correctly identified as negative results. There were only four discrepant cases
in which three VIM carbapenemase producers and one NDM carbapenemase producer were not
detected. The RESIST-5 O.K.N.V.I. assay as an in vitro diagnostic test for detecting five common
carbapenemases provided rapid and accurate results in a short time, indicating that this method
could provide an innovative solution for early detection, resulting in appropriate antimicrobial
treatment in the clinical field.
Keywords: carbapenemase; evaluation; carbapenemase-producing organisms; IMP; VIM; NDM;
KPC; OXA-48-like; RESIST-5 O.K.N.V.I. assay
1. Introduction
The dissemination of carbapenem-resistant organisms is a serious global threat to
human public health with few treatment options for infected patients due to their co-
resistance to other β-lactam antimicrobials [1,2]. Notably, the genes encoding carbapene-
mases, which were reported to be one of the major mechanism for carbapenem resistance,
are mostly located on mobile genetic elements such as transposons, plasmids and genomic
islands. Thus, horizontal transfer of these genes frequently occurs among bacterial species [3].
Therefore, carbapenemase-producing (CP) organisms, including Enterobacterales and glucose-
non-fermenting bacilli (GNFB), have become widespread in several countries,
including South Korea [4,5]. The rapid and accurate detection and identification of car-
bapenemases to prevent further dissemination and to address adequate antimicrobial
treatment of infected patients in the clinical field remain a challenge [6].
Among the diverse types of carbapenemases, the five most prevalent enzymes in Enter-
obacterales and GNFB isolates in South Korea include KPC variants of Ambler class A, three
metallo-β-lactamases (MBLs) of Ambler class B (NDM, VIM and IMP-variants) and OXA-
48-like-variants of Ambler class D [7]. For identifying and characterizing the variable types
of carbapenemases, several diagnostic tools, such as culture-based methods using resistant
phenotypes and molecular biology-based methods using gene amplification, have been
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widely used in clinical microbiology laboratories [8–10]. However, culture-based pheno-
typic methods are labor intensive and time consuming and the molecular method needs
expensive equipment and high expertise. Recently, multiplex immunochromatographic
lateral flow assays for detecting and characterizing carbapenemases were developed [11,12]
and the RESIST-5 O.K.N.V.I. assay (CORIS BioConcept, Gembloux, Belgium) with mem-
brane technology of colloidal gold nanoparticles was introduced to identify five targeted
carbapenemase genes in a single test without specialized equipment within 15 min.
In this study, we evaluated the performance of the RESIST-5 O.K.N.V.I. assay for
detecting the five common carbapenemases (OXA-48-like, KPC, NDM, VIM and IMP)
compared to conventional PCR and sequencing analysis among a large number of clinical
isolates in South Korea.
2. Materials and Methods
2.1. Study Design
A total of 268 non-duplicated clinical isolates of gram-negative bacilli, composed
of 258 CP organisms (KPC producers [n = 40], GES producers [n = 15], NDM producers
[n = 41], VIM producers [n = 42], IMP producers [n = 45], OXA-48-like producers [n = 40],
OXA-23 producers [n = 15] and two or more carbapenemase producers [n = 20]) and 10
non-CP, but carbapenem-resistant Enterobacterales (non-CP CREs), were used to evaluate
the performance of the RESIST-5 O.K.N.V.I. assay kit. The detailed information of tested
isolates including the origin of the isolates is presented in Supplementary Table S1.
2.2. Bacterial Identification
Bacterial identification was performed with MALDI MS using a Bruker MALDI MS
instrument (Bruker, Billerica, MA, USA) and all the isolates were characterized with
conventional PCR and sequence analysis as reference molecular methods.
2.3. Conventional PCR Method
Bacterial DNA was extracted by the thermal lysis method from colonies grown on
MacConkey agar. The PCR was performed under the following amplification conditions:
94 ◦C for 5 min, followed by 30 cycles at 94 ◦C for 30 s, then 58 ◦C (blaKPC) or 60 ◦C (blaIMP,
blaNDM, blaVIM and blaOXA-48-like) for 30 s and 72 ◦C for 30 s, followed by a final extension at
72 ◦C for 5 min using C1000TM Thermal Cycler (Bio-Rad, Hercules, CA, USA) (Table 1) [3].
The primers used in this study are summarized in Table S2.
Table 1. The 268 clinical isolates included in this study.
Carbapenemase (n) Variants (n) Species (n)
KPC (40) KPC-2 (20) K. pneumoniae (10), E. coli (6), Enterobacter species (2), K. oxytoca (1),S. marcescens (1)
KPC-3 (5) K. pneumoniae (4), E. coli (1)
KPC-4 (15) K. pneumoniae (13), E. coli (1), Enterobacter species (1)
GES (15) GES-5 (14) Enterobacter species (6), P. aeruginosa (6), K. pneumoniae (2),
GES-24 (1) P. aeruginosa (1)
IMP (45) IMP-1 (4) K. pneumoniae (3), Enterobacter species (1)
IMP-4 (3) Enterobacter species (3)
IMP-6 (37) P. aeruginosa (37)
IMP-10 (1) P. aeruginosa (1)
NDM (41) NDM-1 (30)
Enterobacter species (9), E. coli (12), K. pneumoniae (4), C. freundii (3),
K. oxytoca (1),
C. amalonaticus (1)
NDM-5 (8) E. coli (7), C. freundii (1)
NDM-7 (2) E. coli (2)
NDM-9 (1) E. coli (1)
Antibiotics 2021, 10, 460 3 of 8
Table 1. Cont.
Carbapenemase (n) Variants (n) Species (n)
VIM (42) VIM-1 (8) K. pneumoniae (4), Enterobacter species (3), C. freundii (1)
VIM-2 (34)
Enterobacter species (23), K. pneumoniae (3), P. aeruginosa (3),
S. marcescens (2), C. freundii (1),
E. coli (1), K. oxytoca (1),
OXA-48-like (40) OXA-232 (40) K. pneumoniae (40)
Co-producers (20)
KPC-2 and NDM-1 (6) K. variicola (2), C. freundii (2), K. oxytoca (1), R. ornithinolytica (1),
KPC-3 and NDM-1 (3) Raoultella planticola (3)
KPC-4 and NDM-1 (1) K. pneumoniae (1)
KPC-4 and NDM-5 (1) K. pneumoniae (1)
NDM-1 and OXA-232 (2) K. pneumoniae (2)
NDM-1 and OXA-181 (3) K. pneumoniae (3)
NDM-5 and OXA-232 (1) K. pneumoniae (1)
GES-5, VIM-2 and OXA-48
(1) C. freundii (1)
IMP-1 and VIM-2 (1) Enterobacter species (1)
VIM-2 and NDM-1 (1) E. coli (1)
OXA-23 (15) OXA-23 (15) Acinetobacter baumannii (15)
Non-CP CRE (10) K. pneumoniae (3), Enterobacter species (3), E. coli (2), K. oxytoca (1),C. freundii (1)
2.4. RESIST-5 O.K.N.V.I. Assay
The RESIST-5 O.K.N.V.I. assay (CORIS BioConcept, Gembloux, Belgium) is a new
immunochromatography test composed of two lateral-flow cassettes (one cassette for VIM
and IMP and the other cassette for OXA-48-like, KPC and NDM) for identification of
five targeted carbapenemases (Figure 1). These tests are based on a membrane technol-
ogy with different colloidal gold nanoparticles. A nitrocellulose membrane is sensitized
with each monoclonal antibody directed against OXA-48-like, KPC, NDM, VIM and IMP
carbapenemases and their variants.
Figure 1. Two lateral-flow cassettes. Each cassette contains one sensitized strip. (A) The type I cassette contains a
nitrocellulose membrane sensitized with monoclonal antibody directed against IMP carbapenemase (“I” line) and VIM
carbapenemase (“V” line) and a control capture reagent (“C” line). (B) The type II cassette contains a nitrocellulose
membrane sensitized with monoclonal antibody directed against NDM carbapenemase (“N” line), KPC carbapenemase
(“K” line) and OXA-48-like carbapenemase (“O” line) and a control capture reagent (“C” line).
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The procedure for the RESIST-5 O.K.N.V.I. assay is as follows: (i) Prepare one semi-
rigid tube and add 12 drops of LY-A buffer (saline solution buffered to pH 7.5 containing
TRIS, NaN3 [<0.1%] and a detergent), (ii) Harvest the bacteria by collecting one colony
on MacConkey agar (BANDIO, Gyeonggi-do, Korea) with a disposable bacteriological
loop and dip the loop in the bottom of the semi-rigid tube containing the buffer, (iii) Stir
thoroughly before removing the loop, (iv) Insert the dropper tightly on the semi-rigid tube,
(v) Vortex the preparation to homogenize (the entire bacterial colony must be suspended
in the buffer), (vi) Invert the test tube and slowly add three drops of diluted sample into
each well of the two cassettes labelled (i) NDM, KPC and OXA-48 and (ii) IMP and VIM
(alternatively, add 100 µl of diluted sample with a micropipette to each cassette sample
well) and (vii) Allow to react for 15 min maximum and read the result.
The results are interpreted as follows for both cassettes. Negative test results are
indicated by a reddish-purple line at the Control line (C) position with no other line present.
Positive test results are indicated by a visible reddish-purple test line at OXA-48-like
(“O” line), KPC (“K” line), NDM (“N” line), VIM (“V” line) and/or IMP (“I” line) in
addition, to a line at the “C” line. A weak line should be considered a positive result.
The results of the RESIST-5 O.K.N.V.I. assay were blindly interpreted by a highly trained
laboratory technician.
3. Results
3.1. Identification of Single Carbapenemase Producers
Table 2 demonstrates the comparison between the results of the RESIST-5 O.K.N.V.I.
assay and the conventional method for detecting carbapenemases used in this study.
All 40 OXA-48-like-producing Klebsiella pneumoniae isolates carrying the blaOXA-232 gene
were correctly identified by the RESIST-5 O.K.N.V.I. assay compared to the conventional
method. In addition, 40 KPC-type carbapenemase-producing organisms including 27 K.
pneumoniae, eight E. coli, three Enterobacter, one Klebsiella oxytoca and one Serratia marcescens
isolate were correctly identified irrespective of KPC variant (KPC-2, KPC-3 and KPC-
4). All 45 IMP-1-, IMP-4-, IMP-6- and IMP-10-producing clinical isolates including 38
Pseudomonas aeruginosa, four Enterobacter and three K. pneumoniae isolates were correctly
identified. Among the 41 NDM-producing clinical isolates including 22 E. coli, nine Enter-
obacter, four K. pneumoniae, four Citrobacter freundii, one Citrobacter amalonaticus and one
K. oxytoca isolate with different NDM variants including NDM-1, NDM-5, NDM-7 and
NDM-9, only one (GNSEV_NDM_38: E. coli carrying the blaNDM-1 gene) showed a false
negative result. Finally, three of 42 VIM-producing clinical isolates including two VIM-1
producing K. pneumoniae isolates (GNSEV_VIM_10 and GNSEV_VIM_32) and one VIM-2
producing Enterobacter isolate (GNSEV_VIM_5) showed false negative results.
Table 2. Results from the RESIST-5 O.K.N.V.I. assay with single carbapenemase-producing isolates stratified according to
the type of carbapenemase.


















KPC 40 (100) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
NDM 0 (0) 40 (97.6) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
VIM 0 (0) 0 (0) 39 (92.9) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
IMP 0 (0) 0 (0) 0 (0) 45 (100) 0 (0) 0 (0) 0 (0) 0 (0)
OXA-48-like 0 (0) 0 (0) 0 (0) 0 (0) 40 (100) 0 (0) 0 (0) 0 (0)
Negative 0 (0) 1 (2.4) 3 (7.1) 0 (0) 0 (0) 15 (100) 15 (100) 10 (100)
To evaluate the four discrepancies, minimum inhibitory concentrations (MICs) were
determined by the broth microdilution method. However, the MICs of imipenem and
meropenem of the GNSEV_NDM_38 strain were 4 mg/L and 8 mg/L, respectively,
which was similar to that of other NDM-producing isolates in this study (imipenem
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MIC50 = 4 mg/L; meropenem MIC50 = 4 mg/L). Three VIM-producing clinical isolates
exhibiting false-negative results showed similar MICs of carbapenems to other VIM-
producing isolates.
3.2. Identification of Multiple Carbapenemase Producers
To evaluate the performance of the RESIST-5 O.K.N.V.I. assay in detecting multiple
carbapenemase producers, 20 clinical Enterobacterales carrying two or more carbapen-
emase genes were tested in this study. The isolates carried six major carbapenemase
variants including combinations of KPC-, GES-, NDM-, VIM-, IMP- and/or OXA-48-like
carbapenemases (Table 1) and all isolates were correctly identified compared with the
conventional methods.
3.3. Identification of Non-Targeted Carbapenemase Producers and Non-CP CRE Isolates
All 15 GES-producing clinical isolates including seven P. aeruginosa, six Enterobacter
and two K. pneumoniae isolates and 15 OXA-23-producing Acinetobacter baumannii were
correctly identified as negative results. In addition, 10 non-CP CRE isolates, which did not
carry five targeted carbapenemases, also showed negative results.
The overall sensitivity, specificity, positive predictive values and negative predictive
values of RESIST-5 O.K.N.V.I. for detecting the five targeted carbapenemases (OXA-48-like,
KPC, NDM, VIM and IMP) in this study are presented in Table 3.












blaKPC 100 (51/51) 100 (217/217) 100 (51/51) 100 (217/217)
blaIMP 100 (46/46) 100 (222/222) 100 (46/46) 100 (222/222)
blaNDM 97.6 (59/60) 100 (208/208) 100(59/59) 99.5 (208/209)
blaVIM 93.3 (42/45) 100 (223/223) 100 (42/42) 98.7 (223/226)
blaOXA-48-like 100 (47/47) 100 (221/221) 100 (47/47) 100 (221/221)
Total 98.4 (245/249) 100 (1091/1091) 100 (245/245) 99.6 (1091/1095)
4. Discussion
Outbreaks of CP organisms carrying KPC-type, MBLs (NDM, VIM and IMP carbapen-
emase), or OXA-type carbapenemases have been reported in many countries and they are
associated with healthcare- and community-acquired infections [1,2,4]. In South Korea,
the most dominant type of carbapenemase is the KPC-type, followed by NDM, OXA-48-
like, VIM and IMP carbapenemase in Enterobacterales [7]. Therefore, rapid and accurate
detection of these five major resistance determinants for carbapenems in clinical isolates is
important for appropriate antimicrobial treatment in infected patients and for prevention
of spread of infection [13]. The gold-standard method of conventional PCR and sequencing
can accurately derive the quantity and subtype of a carbapenemase gene, though deter-
mination of the type of carbapenemase is enough to choose appropriate antimicrobial
treatment in infected patients.
There are several types of diagnostic kits or methods for detecting carbapenemases
from bacterial hosts: (i) carbapenemase inhibition test (CIM) [14], Carba NP test (bioMérieux,
Marcy-l’Étoile, France) [6] and BD PhoenixTM CPO detect test (BD Diagnostic Systems,
Sparks, MD, USA) [15] for phenotypic detection; (ii) Xpert-Carba-R assay test (Cepheid,
Sunnyvale, CA, USA) [16] and PANA RealTyperTM CRE kit test (PANAGENE,
Daejeon, South Korea) [10] for molecular detection; and (iii) Carba 5 assay (NG Biotech,
Guipry, France) [12] for antibody POCT multiplex immunochromatographic lateral flow
assays. According to previous reports, the CIM and Carba NP showed high concordance
rates (100% for Enterobacterales and 98.8% for non-fermenters for both methods) with con-
ventional methods in CP organisms [17]. The BD PhoenixTM CPO detection kit identified
Antibiotics 2021, 10, 460 6 of 8
carbapenemase producers with 97.2% overall agreement rate and it classified Ambler class
A (81.7%), class B (71.8%) and class D (82.0%) carbapenemase producers [15]. For the
molecular detection method, the Xpert Carba-R assay showed overall 100% sensitivity
for detecting five carbapenemases (OXA-48-like, KPC, NDM, VIM and IMP), [16] and the
PANA RealTyperTM CRE kit showed 98.9% to 100% sensitivity for detecting six carbapen-
emases (OXA-48-like, KPC, GES, NDM, VIM and IMP) [10]. The Carba 5 assay reached
100% sensitivity for detecting five carbapenemases (OXA-48-like, KPC, NDM, VIM and
IMP) [12]. However, the tests based on phenotypic methods are often ambiguous in inter-
pretation and time-consuming due to incubation period and molecular methods require
expensive equipment and skilled personnel. Therefore, they have limitations in general
applications. In these regards, the newly developed RESIST-5 O.K.N.V.I. assay based on
multiplex immunochromatographic lateral flow assays has the following advantages: (i) A
single, unique test for detecting five clinically relevant carbapenemases, (ii) no special
equipment required, (iii) easy and clear interpretation and (iv) short time-to-result.
The RESIST-4 O.K.N.V. assay was introduced in 2019 and showed excellent perfor-
mance in detecting the four carbapenemases, OXA-48-like, KPC, NDM and VIM [11].
Recently, the RESIST-5 O.K.N.V.I. assay was released for detecting five carbapenemases
including the additional IMP carbapenemase. In a retrospective study performed on 164
non-duplicated CP Enterobacterales in the National Reference Laboratory for Multidrug-
Resistant Gram-Negative Bacilli in Belgium, KPC and OXA-48-like carbapenemases were
correctly detected with the RESIST-5 O.K.N.V.I. assay and the sensitivity for detection
of the NDM, VIM and IMP carbapenemases was 91.2% (31/34), 90% (36/40) and 84.2%
(16/19), respectively [18]. In our study, all OXA-48-like, KPC and IMP carbapenemase
producers were correctly identified and each carbapenemase in all 20 multiple carbapene-
mase producers included in this study was correctly detected by the RESIST-5 O.K.N.V.I.
assay. In addition, all non-targeted carbapenemase producers including GES- and OXA-
23-producing isolates were correctly identified as negative results, which indicates no
cross-reactivity between Ambler class carbapenemases. Non-CP CRE isolates exhibiting
resistance to carbapenems (disk diffusion zone diameter: 16–23 mm for imipenem and
16–23 mm for meropenem) were correctly identified as negative results.
In this study, only four false negative results were identified including one NDM and
three VIM producers compared to the results of conventional PCR and sequencing method.
VIM carbapenemase has strong hydrolysis activity to carbapenems, but their susceptibility
to carbapenems has been oddly documented as low [7,19]. Inaccurate detection of VIM car-
bapenemase was previously reported in a study on the BD PhoenixTM CPO detect test with
a correct classification rate of 58.6% [15]. The inaccurate detection of VIM carbapenemase
by the RESIST-5 O.K.N.V.I. assay is probably related to low-level expression of purified
recombinant protein [20].
Compared with other previous studies, one of the advantages of this study is that a
large number of carbapenemase-producing isolates, including more than 40 clinical isolates of
each type of carbapenemase producers with many variant genotypes, was included [11,12,17].
Another advantage is that the control group was discreetly selected and included two
domestic, non-targeted, OXA-23 and GES carbapenemase-producing clinical isolates as
well as non-CP CRE clinical isolates to evaluate cross-reactivity among other Ambler class
A and Ambler class D carbapenemases, which are disseminated in South Korea [7,21].
5. Conclusions
Our results suggest that the RESIST-5 O.K.N.V.I. assay has excellent performance in
detection of five targeted carbapenemase genes. In addition, the RESIST-5 O.K.N.V.I. assay
is a rapid, easy and efficient tool to apply in the clinical microbiology laboratory.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/antibiotics10040460/s1, Table S1: List of the isolates included in this study stratified according
to the resistant genotype, Table S2: Primers used in this study.
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